Financial Times
AstraZeneca advances weight-loss pill to take aim at obesity leaders
Pill from drugmaker would put it into competition with market leaders Novo Nordisk and Eli Lilly
View original source — Financial Times ↗
Related stories
MarketWatch
BusinessJun 7, 2026 · 1 min
The Wegovy pill is still dominating the GLP-1 pill market
MarketWatch
CNBC
BusinessJun 8, 2026 · 1 min
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
CNBC
MarketWatch
BusinessJun 6, 2026 · 1 min
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
MarketWatch
MarketWatch
BusinessJun 8, 2026 · 1 min
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
MarketWatch